Central 5-HT1A receptor-mediated modulation of heart rate dynamics and its adjustment by conditioned and unconditioned fear in mice

British Journal of Pharmacology

Volumn 170, Issue 4, 2013, Pages 859-870

  Youn, Jiun ^a   Hager, Torben ^a,b   Misane, Ilga ^c   Pieneman, Anton W ^a   Jansen, René F ^a   Ögren, Sven Ove ^d   Meyer, Michael ^e   Stiedl, Oliver ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b Sylics BV   (Netherlands)

^c JSC Grindeks   (Latvia)

^d KAROLINSKA INSTITUTE   (Sweden)

^e MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

5 Hydroxytryptamine; autonomic nervous system; fear conditioning; non linear dynamics; novelty; radio telemetry

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; LIGAND; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY STIMULATION; BRADYCARDIA; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; EMOTION; EXPERIMENTAL TEST; FEAR; HEART RATE; HEART RATE VARIABILITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RECALL; TACHYCARDIA; 5-HYDROXYTRYPTAMINE; ANIMAL; AUTONOMIC NERVOUS SYSTEM; BRAIN; C57BL MOUSE; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEAR CONDITIONING; HEART; INNERVATION; METABOLISM; NON-LINEAR DYNAMICS; NONLINEAR SYSTEM; NOVELTY; RADIO-TELEMETRY; SIGNAL PROCESSING; TIME;

5-HYDROXYTRYPTAMINE; AUTONOMIC NERVOUS SYSTEM; FEAR CONDITIONING; NON-LINEAR DYNAMICS; NOVELTY; RADIO-TELEMETRY;

ACOUSTIC STIMULATION; ANIMALS; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR, ANIMAL; BRAIN; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; EMOTIONS; FEAR; HEART; HEART RATE; LIGANDS; MALE; MENTAL RECALL; MICE; MICE, INBRED C57BL; NONLINEAR DYNAMICS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SIGNAL PROCESSING, COMPUTER-ASSISTED; TIME FACTORS;

EID: 84885093290     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12325     Document Type: Article

References (56)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl 1): S1-S324.
2. Artigas F, (2013). Developments in the field of antidepressants, where do we go now? Eur Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2013.04.013
3. Audero E, Coppi E, Mlinar B, Rossetti T, Caprioli A, Al Banchaabouchi M, et al. (2008). Sporadic autonomic dysregulation and death associated with excessive serotonin autoinhibition. Science 321: 130-133.
4. Barnes NM, Sharp T, (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083-1152.
5. Bennett DH, (2006). Cardiac Arrhythmias, 7th edn. Hodder-Arnold: London.
6. Bhattacharyya MR, Steptoe A, (2007). Emotional triggers of acute coronary syndromes: strength of evidence, biological processes, and clinical implications. Prog Cardiovasc Dis 49: 353-365.
7. h by 5-HT receptors in mouse CA1 hippocampal neurons. Eur J Neurosci 16: 209-218.
8. 1A syndrome. Pharmacol Biochem Behav 57: 897-908.
9. Bouwknecht JA, Hijzen TH, van der Gugten J, Maes RAA, Olivier B, (2000). Stress-induced hyperthermia in mice: effects of flesinoxan on heart rate and body temperature. Eur J Pharmacol 400: 59-66.
10. Buhot M-C, (1997). Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol 7: 243-254.
11. Carnevali L, Mastorci F, Audero E, Graiani G, Rossi S, Macchi E, et al. (2012). Stress-induced susceptibility to sudden cardiac death in mice with altered serotonin homeostasis. PLoS ONE 7: e41184.
12. Chowdhury N, Quinn JJ, Fanselow MS, (2005). Dorsal hippocampus involvement in trace fear conditioning with long, but not short, trace intervals in mice. Behav Neurosci 119: 1396-1402.
13. Côte F, Fligny C, Fromes Y, Malles J, Vodjdani G, (2004). Recent advances in understanding of serotonin regulation of cardiovascular function. Trends Mol Med 10: 232-238.
14. 7 receptors crosstalk in the regulation of emotional learning: implications for effects of selective serotonin reuptake inhibitors. Neuropharmacology 63: 1150-1160.
15. 1A receptor antagonist. Behav Brain Res 73: 337-353.
16. Hoyer D, Hannon JP, Martin GR, (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554.
17. Ivanov PC, Amaral LAN, Goldberger AL, Havlin S, Rosenblum MG, et al. (1999). Multifractality in human heartbeat dynamics. Nature 399: 461-485.
18. Ivanov PC, Rosenblum MG, Peng C-K, Mietus J, Havlin S, Stanley HE, et al. (1996). Scaling behavior of heartbeat intervals obtained by wavelet-based time-series analysis. Nature 383: 323-327.
19. 1A receptor antagonist, NAD-299. J Pharmacol Exp Ther 283: 216-225.
20. Jordan D, (2005). Vagal control of the heart: central serotonergic mechanisms. Exp Physiol 90: 175-181.
21. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
22. Koolhaas JM, Bartolomucci A, Buwalda B, de Boer SF, Flügge G, Korte SM, et al. (2011). Stress revisited: A critical evaluation of the stress concept. Neurosci Biobehav Rev 34: 1291-1301.
23. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
24. 1A receptor blockade facilitates aversive learning in mice: Interactions with cholinergic and glutamatergic mechanisms. J Pharmacol Exp Ther 316: 581-591.
25. 4 receptors. Eur J Pharmacol 574: 15-19.
26. Meyer M, (2002). Fractal scaling of heart rate dynamics in health and disease. In:, Losa A, Merlini D, Nonnenmacher TF, Weibel ER, (eds). Fractals in Biology and Medicine, Vol. 3. Birkhäuser: Basel, pp. 181-193.
27. Meyer M, Stiedl O, (2003). Self-affine fractal variability of human heartbeat interval dynamics in health and disease. Eur J Appl Physiol 90: 305-316.
28. Meyer M, Stiedl O, (2006). Fractal rigidity by enhanced sympatho-vagal antagonism in heartbeat interval dynamics elicited by central application of corticotropin-releasing factor in mice. J Math Biol 52: 830-874.
29. Misane I, Tovote M, Meyer M, Spiess J, Ögren SO, Stiedl O, (2005). Time-dependent involvement of the dorsal hippocampus in trace fear conditioning in mice. Hippocampus 15: 418-426.
30. 1A receptors in stress-induced cardiac changes: a possible link between mental and cardiac disorders. Clin Exp Pharmacol Physiol 33: 1259-1264.
31. Nalivaiko E, Sgoifo A, (2009). Central 5-HT receptors in cardiovascular control during stress. Neurosci Biobehav Rev 33: 95-106.
32. 1A receptors attenuates tachycardia induced by restraint stress in rats. Am J Physiol Regul Integr Comp Physiol 294: R132-R141.
33. 1A receptor in learning and memory. Behav Brain Res 195: 54-77.
34. Pacher P, Kecskeméti V, (2004). Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des 10: 2463-2475.
35. 1A receptor knockout mice. Neuropharmacology 27: 380-390.
36. Ramage A, (2001). Central cardiovascular regulation and 5-hydroxytryptamine. Brain Res Bull 56: 425-439.
37. Ramage A, Villalõn CM, (2008). 5-hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci 29: 472-481.
38. Ressler KJ, Nemeroff CB, (2000). Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12 (Suppl 1): 2-19.
39. 1A receptor function in major depressive disorder. Prog Neurobiol 88: 17-31.
40. Stiedl O, Meyer M, (2003). Cardiac dynamics in corticotropin-releasing factor receptor subtype 2-deficient mice. Neuropeptides 37: 3-16.
41. Stiedl O, Spiess J, (1997). Effect of tone-dependent fear conditioning on heart rate and behavior of C57BL/6N mice. Behav Neurosci 111: 703-711.
42. Stiedl O, Radulovic J, Lohmann R, Birkenfeld K, Palve M, Kammermeier J, et al. (1999). Strain and substrain differences in context- and tone-dependent fear conditioning of inbred mice. Behav Brain Res 104: 1-12.
43. 1A receptors in classical fear conditioning in C57BL/6J mice. J Neurosci 20: 8515-8527.
44. Stiedl O, Birkenfeld K, Palve M, Spiess J, (2000b). Impairment of conditioned contextual fear of C57BL/6J mice by intracerebral injections of the NMDA receptor antagonist APV. Behav Brain Res 116: 157-168.
45. Stiedl O, Tovote P, Ögren SO, Meyer M, (2004). Behavioral and autonomic dynamics during contextual fear conditioning in mice. Auton Neurosci 115: 15-27.
46. Stiedl O, Meyer M, Jahn O, Ögren SO, Spiess J, (2005). Corticotropin-releasing factor receptor 1 and central heart rate regulation in mice during expression of conditioned fear. J Pharmacol Exp Ther 312: 905-916.
47. 2C receptors causes hypolocomotion without anxiogenic-like cardiovascular adjustments in mice. Neuropharmacology 52: 949-957.
48. Stiedl O, Jansen RF, Pieneman AW, Ögren SO, Meyer M, (2009). Assessing aversive emotional states through the heart in mice: implications for cardiovascular dysregulation in affective disorders. Neurosci Biobehav Rev 33: 181-190.
49. Tovote P, Meyer M, Beck-Sickinger AG, von Hörsten S, Ögren SO, Spiess J, et al. (2004). Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue. Regul Pept 120: 205-214.
50. Tovote P, Meyer M, Ronnenberg A, Ögren SO, Spiess J, Stiedl O, (2005). Heart rate dynamics and behavioral responses during acute emotional challenge in corticotropin-releasing factor receptor 1-deficient and corticotropin-releasing factor overexpressing mice. Neuroscience 134: 1113-1122.
51. Unterecker S, Warrings B, Deckert J, Pfuhlmann B, (2012). Correlation of QTc interval prolongation and serum level of citalopram after intoxication-a case report. Pharmacopsychiatry 45: 30-34.
52. 1A receptor activation: sympathoinhibition or anxiolysis? Am J Physiol Regul Integr Comp Physiol 297: R495-R501.
53. Villalõn CM, Centuriõn D, (2007). Cardiovascular responses induced by 5-hydroxytryptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol 376: 45-63.
54. Vogelzangs N, Seldenrijk A, Beekman ATF, van Hout HPJ, de Jonge P, Penninx BWJH, (2010). Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord 125: 241-248.
55. 1A receptor ligands with contrasting intrinsic activities. Neuropharmacology 57: 567-576.
56. Zareba W, (2007). Drug induced QT prolongation. Cardiol J 14: 523-533.